Aclaris Therapeutics (ACRS) – Trader Talk
-
Aclaris Therapeutics (ACRS) Climbs 70% Following Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for RA
-
Short report surfaces on Aclaris Therapeutics (ACRS), calling for stock to go to $5
Back to ACRS Stock Lookup